|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:AK7-MYC (FusionGDB2 ID:HG122481TG4609) |
Fusion Gene Summary for AK7-MYC |
Fusion gene summary |
Fusion gene information | Fusion gene name: AK7-MYC | Fusion gene ID: hg122481tg4609 | Hgene | Tgene | Gene symbol | AK7 | MYC | Gene ID | 122481 | 4609 |
Gene name | adenylate kinase 7 | MYC proto-oncogene, bHLH transcription factor | |
Synonyms | AK 7|CFAP75|FAP75|SPGF27 | MRTL|MYCC|bHLHe39|c-Myc | |
Cytomap | ('AK7')('MYC') 14q32.2 | 8q24.21 | |
Type of gene | protein-coding | protein-coding | |
Description | adenylate kinase 7ATP-AMP transphosphorylase 7putative adenylate kinase 7 | myc proto-oncogene proteinavian myelocytomatosis viral oncogene homologclass E basic helix-loop-helix protein 39myc-related translation/localization regulatory factorproto-oncogene c-Myctranscription factor p64v-myc avian myelocytomatosis viral onco | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | Q96M32 | . | |
Ensembl transtripts involved in fusion gene | ENST00000267584, ENST00000554313, ENST00000555570, | ||
Fusion gene scores | * DoF score | 3 X 3 X 1=9 | 24 X 26 X 9=5616 |
# samples | 3 | 36 | |
** MAII score | log2(3/9*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(36/5616*10)=-3.96347412397489 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: AK7 [Title/Abstract] AND MYC [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | AK7(96937669)-MYC(128753520), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | AK7 | GO:0006165 | nucleoside diphosphate phosphorylation | 23416111 |
Hgene | AK7 | GO:0009142 | nucleoside triphosphate biosynthetic process | 23416111 |
Tgene | MYC | GO:0000122 | negative regulation of transcription by RNA polymerase II | 9924025|19160485 |
Tgene | MYC | GO:0006338 | chromatin remodeling | 21533051 |
Tgene | MYC | GO:0006879 | cellular iron ion homeostasis | 9924025 |
Tgene | MYC | GO:0006974 | cellular response to DNA damage stimulus | 17873522 |
Tgene | MYC | GO:0007050 | cell cycle arrest | 10962037 |
Tgene | MYC | GO:0008284 | positive regulation of cell proliferation | 15994933|19160485 |
Tgene | MYC | GO:0010332 | response to gamma radiation | 19179467 |
Tgene | MYC | GO:0010468 | regulation of gene expression | 21447833 |
Tgene | MYC | GO:0010628 | positive regulation of gene expression | 15459207 |
Tgene | MYC | GO:0032986 | protein-DNA complex disassembly | 19160485 |
Tgene | MYC | GO:0035690 | cellular response to drug | 17873522|19179467 |
Tgene | MYC | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 19179467 |
Tgene | MYC | GO:0045893 | positive regulation of transcription, DNA-templated | 10962037|17558397|18818310 |
Tgene | MYC | GO:0045944 | positive regulation of transcription by RNA polymerase II | 10723141 |
Tgene | MYC | GO:0048146 | positive regulation of fibroblast proliferation | 9924025|18987311 |
Tgene | MYC | GO:0048147 | negative regulation of fibroblast proliferation | 10962037 |
Tgene | MYC | GO:0050679 | positive regulation of epithelial cell proliferation | 18987311 |
Tgene | MYC | GO:0051276 | chromosome organization | 10962037 |
Tgene | MYC | GO:0051782 | negative regulation of cell division | 10962037 |
Tgene | MYC | GO:0070371 | ERK1 and ERK2 cascade | 15459207 |
Tgene | MYC | GO:0071456 | cellular response to hypoxia | 15459207 |
Tgene | MYC | GO:2001022 | positive regulation of response to DNA damage stimulus | 19179467 |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for AK7-MYC |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for AK7-MYC |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for AK7-MYC |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:96937669/:128753520) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
AK7 | . |
FUNCTION: Nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. Has highest activity toward AMP, and weaker activity toward dAMP, CMP and dCMP. Also displays broad nucleoside diphosphate kinase activity. Involved in maintaining ciliary structure and function. {ECO:0000269|PubMed:21080915, ECO:0000269|PubMed:23416111}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for AK7-MYC |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for AK7-MYC |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for AK7-MYC |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for AK7-MYC |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | AK7 | C4693784 | SPERMATOGENIC FAILURE 27 | 1 | UNIPROT |
Tgene | C0007102 | Malignant tumor of colon | 4 | CTD_human | |
Tgene | C0009375 | Colonic Neoplasms | 4 | CTD_human | |
Tgene | C2239176 | Liver carcinoma | 4 | CTD_human | |
Tgene | C0007621 | Neoplastic Cell Transformation | 3 | CTD_human | |
Tgene | C0019207 | Hepatoma, Morris | 3 | CTD_human | |
Tgene | C0019208 | Hepatoma, Novikoff | 3 | CTD_human | |
Tgene | C0023904 | Liver Neoplasms, Experimental | 3 | CTD_human | |
Tgene | C0033578 | Prostatic Neoplasms | 3 | CTD_human | |
Tgene | C0086404 | Experimental Hepatoma | 3 | CTD_human | |
Tgene | C0376358 | Malignant neoplasm of prostate | 3 | CTD_human | |
Tgene | C0023903 | Liver neoplasms | 2 | CTD_human | |
Tgene | C0024121 | Lung Neoplasms | 2 | CTD_human | |
Tgene | C0024623 | Malignant neoplasm of stomach | 2 | CTD_human | |
Tgene | C0038356 | Stomach Neoplasms | 2 | CTD_human | |
Tgene | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CTD_human | |
Tgene | C0235874 | Disease Exacerbation | 2 | CTD_human | |
Tgene | C0242379 | Malignant neoplasm of lung | 2 | CTD_human | |
Tgene | C0345904 | Malignant neoplasm of liver | 2 | CTD_human | |
Tgene | C1708349 | Hereditary Diffuse Gastric Cancer | 2 | CTD_human | |
Tgene | C0001418 | Adenocarcinoma | 1 | CTD_human | |
Tgene | C0005684 | Malignant neoplasm of urinary bladder | 1 | CTD_human | |
Tgene | C0005695 | Bladder Neoplasm | 1 | CTD_human | |
Tgene | C0006826 | Malignant Neoplasms | 1 | CGI;CTD_human | |
Tgene | C0007097 | Carcinoma | 1 | CTD_human | |
Tgene | C0007129 | Merkel cell carcinoma | 1 | CTD_human | |
Tgene | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human | |
Tgene | C0007137 | Squamous cell carcinoma | 1 | CTD_human | |
Tgene | C0007194 | Hypertrophic Cardiomyopathy | 1 | CTD_human | |
Tgene | C0007873 | Uterine Cervical Neoplasm | 1 | CTD_human | |
Tgene | C0008924 | Cleft upper lip | 1 | CTD_human | |
Tgene | C0008925 | Cleft Palate | 1 | CTD_human | |
Tgene | C0009402 | Colorectal Carcinoma | 1 | CTD_human | |
Tgene | C0009404 | Colorectal Neoplasms | 1 | CTD_human | |
Tgene | C0014170 | Endometrial Neoplasms | 1 | CTD_human | |
Tgene | C0015695 | Fatty Liver | 1 | CTD_human | |
Tgene | C0017636 | Glioblastoma | 1 | CTD_human | |
Tgene | C0018923 | Hemangiosarcoma | 1 | CTD_human | |
Tgene | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human | |
Tgene | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human | |
Tgene | C0025149 | Medulloblastoma | 1 | CTD_human | |
Tgene | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human | |
Tgene | C0027627 | Neoplasm Metastasis | 1 | CTD_human | |
Tgene | C0027651 | Neoplasms | 1 | CTD_human | |
Tgene | C0027819 | Neuroblastoma | 1 | CGI;CTD_human | |
Tgene | C0029463 | Osteosarcoma | 1 | CTD_human | |
Tgene | C0030297 | Pancreatic Neoplasm | 1 | CTD_human | |
Tgene | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human | |
Tgene | C0085413 | Polycystic Kidney, Autosomal Dominant | 1 | CTD_human | |
Tgene | C0086692 | Benign Neoplasm | 1 | CTD_human | |
Tgene | C0149721 | Left Ventricular Hypertrophy | 1 | CTD_human | |
Tgene | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human | |
Tgene | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human | |
Tgene | C0205643 | Carcinoma, Cribriform | 1 | CTD_human | |
Tgene | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human | |
Tgene | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human | |
Tgene | C0205696 | Anaplastic carcinoma | 1 | CTD_human | |
Tgene | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human | |
Tgene | C0205698 | Undifferentiated carcinoma | 1 | CTD_human | |
Tgene | C0205699 | Carcinomatosis | 1 | CTD_human | |
Tgene | C0205833 | Medullomyoblastoma | 1 | CTD_human | |
Tgene | C0206093 | Neuroectodermal Tumors | 1 | CTD_human | |
Tgene | C0278510 | Childhood Medulloblastoma | 1 | CTD_human | |
Tgene | C0278876 | Adult Medulloblastoma | 1 | CTD_human | |
Tgene | C0333704 | Chromosome Breaks | 1 | CTD_human | |
Tgene | C0334588 | Giant Cell Glioblastoma | 1 | CTD_human | |
Tgene | C0346647 | Malignant neoplasm of pancreas | 1 | CTD_human | |
Tgene | C0376628 | Chromosome Breakage | 1 | CTD_human | |
Tgene | C0476089 | Endometrial Carcinoma | 1 | CTD_human | |
Tgene | C0751291 | Desmoplastic Medulloblastoma | 1 | CTD_human | |
Tgene | C0887850 | Polycystic Kidney, Type 1 Autosomal Dominant Disease | 1 | CTD_human | |
Tgene | C0919267 | ovarian neoplasm | 1 | CTD_human | |
Tgene | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human | |
Tgene | C1176475 | Ductal Carcinoma | 1 | CTD_human | |
Tgene | C1275668 | Melanotic medulloblastoma | 1 | CTD_human | |
Tgene | C1621958 | Glioblastoma Multiforme | 1 | CTD_human | |
Tgene | C1837218 | Cleft palate, isolated | 1 | CTD_human | |
Tgene | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human | |
Tgene | C2711227 | Steatohepatitis | 1 | CTD_human | |
Tgene | C2713368 | Hematopoetic Myelodysplasia | 1 | CTD_human | |
Tgene | C2751306 | Polycystic kidney disease, type 2 | 1 | CTD_human | |
Tgene | C3463824 | MYELODYSPLASTIC SYNDROME | 1 | CTD_human | |
Tgene | C4048328 | cervical cancer | 1 | CTD_human | |
Tgene | C4551472 | Hypertrophic obstructive cardiomyopathy | 1 | CTD_human |